Impact of prognostic factors and risk groups on overall survival in patients treated with pembrolizumab vs investigator’s choice chemotherapy for advanced urothelial cancer: Post HOC analysis of Keynote-045 Meeting Abstract
| Authors: | Gurney, H.; Bellmunt, J.; de Wit, R.; Vaughn, D. J.; Fradet, Y.; Lee, J. L.; Fong, L.; Vogelzang, N. J.; Climent, M. A.; Petrylak, D. P.; Choueiri, T. K.; Necchi, A.; Gerritsen, W.; Quinn, D. I.; Culine, S.; Sternberg, C. N.; Jensen, E.; Frenkl, T.; Perini, R. F.; Bajorin, D. F. |
| Abstract Title: | Impact of prognostic factors and risk groups on overall survival in patients treated with pembrolizumab vs investigator’s choice chemotherapy for advanced urothelial cancer: Post HOC analysis of Keynote-045 |
| Meeting Title: | 2019 Annual Scientific Meeting of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) |
| Journal Title: | Asia-Pacific Journal of Clinical Oncology |
| Volume: | 15 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2019 Jul 21-23 |
| Meeting Location: | Brisbane, Australia |
| ISSN: | 1743-7555 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2019-07-01 |
| Start Page: | 31 |
| Language: | English |
| ACCESSION: | WOS:000476915200008 |
| DOI: | 10.1111/ajco.13185 |
| PROVIDER: | wos |
| PUBMED: | 31339635 |
| Notes: | Meeting Abstract: abs7 -- Source: Wos |
